Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

166 DECITABINE
Peripheral edema (25%)
Petechiae (39%)
Pruritus (11%)
Rash (sic) (19%)
(2000): Schwartsmann G+, Invest New Drugs 18(1), 83 (with
cisplatin)
Urticaria (6%)
Mucosal
Gingival bleeding (8%)
Glossodynia (5%)
Lip ulceration (5%)
Mucositis
(2000): Schwartsmann G+, Invest New Drugs 18(1), 83 (with
cisplatin)
(1997): Schwartsmann G+, Leukemia Suppl 1, S28 (with
daunorubicin)
Oral candidiasis (6%)
Stomatitis (12%)
Tongue ulceration (7%)
Hair
Hair – alopecia
(1997): Schwartsmann G+, Leukemia Suppl 1, S28 (with
daunorubicin)
Eyes
Vision blurred (6%)
Other
Abdominal pain (14%)
Anaphylactoid reactions/Anaphylaxis
Cough (40%)
Fever (53%)
Hypersensitivity
Infections
(2000): Wijermans P+, J Clin Oncol 18(5), 956
Injection-site edema (5%)
Myalgia/Myositis/Myopathy/Myotoxicity (5%)
Pain (13%)
Upper respiratory infection
DEFERASIROX
Trade name: Exjade (Novartis)
Indications: Chronic iron overload due to blood transfusions
Category: Chelator, iron
Half-life: 8–16 hours
Clinically important, potentially hazardous interactions
with: N/A
Reactions
Skin
Purpura
Rash (sic) (8%)
(2007): Vichinsky E+, Br J Haematol 136(3), 501
(2006): Cappellini MD+, Blood 107(9), 3455
(2006): Vanorden HE+, Ann Pharmacother 40(6), 1110
Urticaria (4%)
Eyes
Cataract
Ocular pressure
Visual disturbances
Other
Abdominal pain (14%)
(2007): Vichinsky E+, Br J Haematol 136(3), 501
Cough (14%)
Upper respiratory infection (9%)
DEFEROXAMINE
Trade names: Desferal (Novartis); Desferin
Indications: Hemochromatosis, acute iron overload
Category: Chelator, iron
Half-life: 6.1 hours
Clinically important, potentially hazardous interactions
with: ascorbic acid, zinc
Reactions
Skin
Acne
Angioedema
(1984): Romeo MA+, J Inherited Metab Dis 7, 121
Depigmentation
(2001): Lopez L+, Dermatol Surg 27(9), 795
Dermatitis
(1988): Venencie PY+, Ann Dermatol Venereol (French)
115, 1174
Edema (